NanoLogix (Pink Sheets: NNLX), a biotechnology innovation in the rapid detection and identification of live cells of bacteria and microorganisms, announced today its BioNanoFilter (BNF) technology will be the subject of a clinical trial, led by Dr. Gian Carlo Di Renzo, University of Perugia in Italy. The trial will study 300 patients, the speed and accuracy NanoLogix technology beyond the current methods for detection and identification of group B streptococci (GBS) in pregnant women. This is 8 to 24 times faster than traditional methods. The process will be the second trial of the technology NanoLogix BNF for group A streptococcal BI results of this study will help to speed up the approval of the kit BNF for use in Europe, North Africa and Middle East.Based on the success of construction activities and other ASM, the company is shipping test kits and BNP at the BNF and the use of the USDA and a large food-processing company, during the month of June The kit should be used for internal processing of food tests.
Conventional technologies can take at least 48-72 hours to return results for Group B Strep. Often during this waiting period, it is recommended that physicians treat patients empirically if they fall clear ‘at risk’ for the categories of being colonized with GBS. This practice protects the mother of the risks to health and the unborn child from a fatal disease associated with Streptococcus group B, however, can also lead to the development of antibiotic resistance in strains of GBS.
About 30 % of women of childbearing age carry GBS, which can cause life-threatening infections such as sepsis and the neonate, if their mothers are not treated prior to delivery. United States, results in nearly 8000 untreated children infected each year. The Centers for Disease Control guidelines for prevention of neonatal GBS calls for testing all pregnant women for GBS between 35 and 37 weeks. In 2009, just over 4 million women gave birth in the United States alone.
The first phase of the ‘University of Texas Health Science Center clinical trial has been accepted for publication in magazines with a big. The name of the magazine will be announced at the publication of UTHSC.